Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated
with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the
clinical circumstances as discussed in this article.
If ticagrelor is used, the dose of aspirin must not exceed 100 mg daily. Prasugrel must not be used in patients with a
history of stroke or transient ischemic attack. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple
antiplatelet drug therapy if there is an increased risk for bleeding or in non-high-risk patients such as those with a normal
baseline cardiac troponin level, nondiabetics, and those aged 75 years and older in whom potential benefit may be
significantly offset by the potential risk of bleeding. Clinical trial data in patients with acute coronary syndromes do not
support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients.
Keywords: Acute coronary syndromes, unstable angina pectoris, non-ST-elevation myocardial infarction, aspirin, clopidogrel,
prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, cangrelor, voraxapar.
Rights & PermissionsPrintExport